Evidence map›Paper›PMID 25284075›Full record

ArticleScientific reports2014

Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.

Yifeng Sun, Chang Chen, Peng Zhang, Huikang Xie, Likun Hou, Zheng Hui, Yongjie Xu, Qiaoling Du, Xiao Zhou, Bo Su and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinicopathological implications of miR-3127 in melanoma.Journal of pathology and translational medicine · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yifeng Sun1] Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China [2] Department of Thoracic Surgery, Shanghai Chest Hospital Affiliated Shanghai Jiaotong University, No. 241, Huaihaixi Road, Shanghai, 200030, P.R. China [3].
Chang Chen1] Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China [2].
Peng Zhang1] Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China [2].
Huikang XieCentral Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China.
Likun HouDepartment of pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China.
Zheng HuiDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China.
Yongjie XuDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China.
Qiaoling DuDepartments of Gynaecology and Obstetrics, Shanghai First Maternity and Infant Health Hospital. Tongji University School of Medicine, No. 536, Changle Road, Shanghai, 200126, P.R. China.
Xiao ZhouDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China.
Bo SuCentral Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai, 200433, P.R. China.
Wen GaoDepartment of Thoracic Surgery, Shanghai Chest Hospital Affiliated Shanghai Jiaotong University, No. 241, Huaihaixi Road, Shanghai, 200030, P.R. China.
Shanghai Pulmonary Hospital · CNTongji University · CNShanghai Chest Hospital · CNShanghai First Maternity and Infant Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR-3127-5p is a primate-specific miRNA which is down-regulated in recurrent NSCLC tissue vs. matched primary tumor tissue (N = 15) and in tumor tissue vs. normal lung tissue (N = 177). Reduced miR-3127-5p expression is associated with a higher Ki-67 proliferation index and unfavorable prognosis in NSCLC. Overexpression of miR-3127-5p significantly reduced NSCLC cells proliferation, migration, and motility in vitro and in vivo. The oncogene ABL1 was a direct miR-3127-5p target, and miR-3127-5p regulated the activation of the Abl/Ras/ERK pathway and transactivated downstream proliferation/metastasis-associated molecules. Overexpression of miR-3127-5p in A549 or H292 cells resulted in enhanced resistance to dasatinib, an Abl/src tyrosine kinase inhibitor. miR-3127-5p expression levels were correlated with dasatinib sensitivity in NSCLC cell lines without K-Ras G12 mutation. In conclusion, miR-3127-5p acts as a tumor suppressor gene and is a potential biomarker for dasatinib sensitivity in the non-mutated Ras subset of NSCLC.

Indexed as

Drug Resistance, NeoplasmGene Expression Regulation, NeoplasticAdenocarcinomaAgedAnimalsApoptosisBiomarkers, TumorBlotting, WesternCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell AdhesionCell MovementCell ProliferationDasatinibFemaleBiomarkers, TumorDasatinibMAPK1 protein, humanMicroRNAsMIRN3127 microRNA, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Protein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrimidinesras ProteinsRNA, MessengerThiazoles

Identifiers

PMID25284075
PMCPMC5377463
OpenAlexW1975266356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.